2026 Annual Meeting | Industry Therapeutic Update from Kyverna: Miv-cel CD19 CAR T: Reimagining Treatment for Neurologic Autoimmune Diseases?

��ɫ��

2026 Annual Meeting | Industry Therapeutic Update from Kyverna: Miv-cel CD19 CAR T: Reimagining Treatment for Neurologic Autoimmune Diseases?

Date Saturday 04/18/26

Time 06:00 PM - 08:00 PM CDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Warner Biddle

Topic(s) Autoimmune Neurology

Learning Objectives This symposium will examine the rationale for CD19-directed CAR T-cell therapies in B cell–driven neurologic autoimmune diseases. Attendees will review emerging clinical data from miv-cel (mivocabtagene autoleucel, formerly KYV-101), an investigational CD19 CAR T-cell therapy, and discuss key considerations relevant to CAR T-cell therapy in neuroautoimmune populations, with a focus on stiff person syndrome and myasthenia gravis.

CME Available No CME available

Event Timeline
06:00 PM - 08:00 PM CDT	Speaker	Industry Therapeutic Update from Kyverna: Miv-cel CD19 CAR T: Reimagining Treatment for Neurologic Autoimmune Diseases? Warner Biddle

Faculty Disclosures
Warner Biddle	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��